Stock Market Today, Feb: ImmunityBio Up on Anktiva EU OK
ImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
This volatility comparison pits the dividend aristocrats ETF against the SP500 to help you evaluate relative risk and inform allocation decisions.
20,523 articlesImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
U.S. stocks rebound Tuesday after Monday’s tariff-driven drop, with the S&P 500 and Dow clawing back losses as invest...
A dramatic surge in a single year can turn heads, but investors need more than headlines. This article dives into whe...
As March arrives, the quantum computing space presents both risk and opportunity. This guide highlights two sturdy pi...
On March 2, energy and defense names spearheaded gains as oil jumped, while travel and leisure stocks softened. This ...
Geopolitical headlines drove a rush to buy the dip, yet the rebound failed to materialize for many investors. The epi...
When a solar stock down year meets a bold 75 million bet on Enphase Energy, investors gain a rare glimpse into how co...
Today’s session showed a rally fade for Plug Power and a broader pullback in hydrogen names. This article breaks down...
Nebius stock has drawn attention with recent deals and rising prices. This guide explores whether could buying Nebius...
Stocks opened sharply lower on May 15, 2026, pushing the S&P 500 onto a heavier red backdrop as tech weakness and inf...
May 21 is shaping up as a potential market catalyst. This guide explains what could drive a huge stock move and offer...
The idea of a bargain in the cruise sector is enticing, but cheap can be risky. This article breaks down how to judge...